Biocon, an Indian biopharmaceutical company, is strategically positioning itself to dominate the global insulin market, as chairperson Kiran Mazumdar-Shaw emphasizes the company's ambition to be recognized as 'the' insulin company. This comes at a time when larger competitors like Novo Nordisk and Eli Lilly are increasingly focusing on GLP-1 therapies, which offer higher margins and superior clinical outcomes. Shaw noted that while GLP-1 drugs are promising, they cannot replace insulin for Type-1 diabetics and late-stage Type-2 patients, ensuring insulin remains essential. Biocon reported a biosimilars revenue of ₹7,676 crore (approximately $925 million USD) for the first nine months of FY26, with insulin being a key segment. The global insulin market is expected to reach $29–31 billion by 2025, with India contributing around $650–700 million. To capitalize on this opportunity, Biocon plans to double its insulin production capacity at its facility in Malaysia by FY27. Additionally, the company is expanding its GLP-1 pipeline, with launches in Europe and filings in the U.S. and Latin America. As the market evolves, Biocon aims to enhance its commercial execution and improve cash flow generation, positioning itself for future growth.